NCCN 2016 Congress Series™: Lung Cancer
Lung cancer is the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for approximately 83% of all lung cancers and occurring primarily in older patients with a median age at diagnosis of 70 years. These statistics emphasize an educational need for health care professionals to know how to assess older patients with NSCLC, to determine risk for adverse outcomes from cancer treatment, and to identify treatment options that may be more appropriate for older patients at higher risk.
With the emergence of new therapeutic interventions and systemic therapies for NSCLC and advances in lung cancer screening, clinicians continue to rely on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer, the NCCN Guidelines® for Older Adult Oncology, and NCCN’s educational interventions to increase their knowledge and to bridge the gap between knowledge and clinical practice. With these resources, NCCN seeks to assist clinicians in communicating management options effectively to their patients, making shared treatment decisions, and providing optimal care.
This congress is designed to educate healthcare professionals on current and emerging scientific data so that they can make evidence-based decisions about screening and treatment for patients with NSCLC. The goal of this educational program is to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists, and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practices and healthcare settings for patients with NSCLC.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with non-small cell lung cancer.
Following this activity, participants should be able to:
Treatment of Older Adult Patients with Non-Small Cell Lung Cancer (NSCLC)
• Apply into practice tools--such as risk factor algorithm, frailty assessment, geriatric assessment, and performance status--to assess whether older patients with NSCLC can tolerate certain therapeutic interventions.
• Assess the risks and benefits of therapeutic interventions in the management of older patients with NSCLC who are at higher risk for adverse events from therapy.
Immunotherapy in Patients with Non-Small Cell Lung Cancer
• Describe recent updates regarding the use of immunotherapy as subsequent therapy for patients with metastatic NSCLC.
• Implement the use of biomarkers to identify patients with metastatic NSCLC who may be candidates for immunotherapy.
• Identify the unique side effects that may occur with immunotherapy and describe how to manage the side effects in patients with non-small cell lung cancer.
Sequencing Targeted Therapy for Patients with Metastatic Non-Small Cell Lung Cancer
• Review recent updates for targeted therapies in management of patients with metastatic NSCLC.
• Appropriately sequence targeted therapies in treatment of patients with metastatic NSCLC.
Minimizing Risks from Lung Cancer Screening
• Describe the risks and benefits of lung cancer screening.
• Identify recent strategies to minimize risks from lung cancer screening.
• Participate in shared patient/physician decision making to determine whether lung cancer screening is appropriate for an individual patient.
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
National Comprehensive Cancer Network designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 3.0 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 3.0 contact hour(s) (0.3 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-050-L01-P
- 3.00 ACPE contact hours
- 3.00 AMA PRA Category 1 Credit™
- 3.00 ANCC contact hours
- 3.00 Participation